News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Altus Pharmaceuticals Inc. And Dr. Falk Pharma GmbH Announce TheraCLEC Granted Orphan Drug Designation By The European Medicines Evaluation Agency


10/19/2005 5:11:48 PM

Altus Pharmaceuticals Inc. and Dr. Falk Pharma GmbH announced today that TheraCLEC(TM) was granted orphan drug designation by the European Medicines Evaluation Agency (EMEA). TheraCLEC was granted designation for the treatment of malabsorption due to exocrine pancreatic insufficiency, a condition most often found in patients suffering from cystic fibrosis (CF), chronic pancreatitis (CP), pancreatic cancer as well as other diseases where the pancreas is not producing sufficient amounts of endogenous enzymes required for proper nutrition.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES